PMID- 26528698
OWN - NLM
STAT- MEDLINE
DCOM- 20160922
LR  - 20181113
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 6
IP  - 38
DP  - 2015 Dec 1
TI  - Interleukin 6 trigged ataxia-telangiectasia mutated activation facilitates lung 
      cancer metastasis via MMP-3/MMP-13 up-regulation.
PG  - 40719-33
LID - 10.18632/oncotarget.5825 [doi]
AB  - Our previous studies show that the phosphorylation of ataxia-telangiectasia 
      mutated (ATM) induced by interleukin 6 (IL-6) treatment contributes to multidrug 
      resistance formation in lung cancer cells, but the exact role of ATM activation 
      in IL-6 increased metastasis is still elusive. In the present study, matrix 
      metalloproteinase-3 (MMP-3) and MMP-13 were firstly demonstrated to be involved 
      in IL-6 correlated cell migration. Secondly, IL-6 treatment not only increased 
      MMP-3/MMP-13 expression but also augmented its activities. Thirdly, the 
      inhibition of ATM phosphorylation efficiently abolished IL-6 up-regulating 
      MMP-3/MMP-13 expression and increasing abilities of cell migration. Most 
      importantly, the in vivo test showed that the inhibition of ATM abrogate the 
      effect of IL-6 on lung cancer metastasis via MMP-3/MMP-13 down-regulation. Taken 
      together, these findings demonstrate that IL-6 inducing ATM phosphorylation 
      increases the expression of MMP-3/MMP-13, augments the abilities of cell 
      migration, and promotes lung cancer metastasis, indicating that ATM is a 
      potential target molecule to overcome IL-6 correlated lung cancer metastasis.
FAU - Jiang, Yi Na
AU  - Jiang YN
AD  - Department of Immunology, Basic Medicine Science, Medical College, Xiamen 
      University, Xiamen 361005, People's Republic of China.
FAU - Yan, Hong Qiong
AU  - Yan HQ
AD  - Department of Immunology, Basic Medicine Science, Medical College, Xiamen 
      University, Xiamen 361005, People's Republic of China.
FAU - Huang, Xiao Bo
AU  - Huang XB
AD  - Department of Immunology, Basic Medicine Science, Medical College, Xiamen 
      University, Xiamen 361005, People's Republic of China.
FAU - Wang, Yi Nan
AU  - Wang YN
AD  - Department of Immunology, Basic Medicine Science, Medical College, Xiamen 
      University, Xiamen 361005, People's Republic of China.
FAU - Li, Qing
AU  - Li Q
AD  - Department of Immunology, Basic Medicine Science, Medical College, Xiamen 
      University, Xiamen 361005, People's Republic of China.
FAU - Gao, Feng Guang
AU  - Gao FG
AD  - Department of Immunology, Basic Medicine Science, Medical College, Xiamen 
      University, Xiamen 361005, People's Republic of China.
AD  - State Key Laboratory of Oncogenes and Related Genes, Shang Hai Jiao Tong 
      University, Shanghai 200032, People's Republic of China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (IL6 protein, human)
RN  - 0 (Interleukin-6)
RN  - 0 (RNA, Messenger)
RN  - EC 2.7.11.1 (Ataxia Telangiectasia Mutated Proteins)
RN  - EC 3.4.24.- (Matrix Metalloproteinase 13)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Ataxia Telangiectasia Mutated Proteins/genetics/*metabolism
MH  - Blotting, Western
MH  - Cell Movement/drug effects
MH  - Cell Proliferation/drug effects
MH  - Gene Expression Regulation, Neoplastic/*drug effects
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Interleukin-6/*pharmacology
MH  - Lung Neoplasms/drug therapy/metabolism/*secondary
MH  - Matrix Metalloproteinase 13/genetics/*metabolism
MH  - Matrix Metalloproteinase 3/genetics/*metabolism
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - Phosphorylation/drug effects
MH  - RNA, Messenger/genetics
MH  - Real-Time Polymerase Chain Reaction
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Tumor Cells, Cultured
MH  - Xenograft Model Antitumor Assays
PMC - PMC4747364
OTO - NOTNLM
OT  - ataxia-telangiectasia mutated
OT  - interleukin 6
OT  - lung cancer
OT  - matrix metalloproteinases
OT  - metastasis
COIS- CONFLICTS OF INTERESTS The authors have no conflicts of interests to declare.
EDAT- 2015/11/04 06:00
MHDA- 2016/09/23 06:00
PMCR- 2015/12/01
CRDT- 2015/11/04 06:00
PHST- 2015/05/20 00:00 [received]
PHST- 2015/09/23 00:00 [accepted]
PHST- 2015/11/04 06:00 [entrez]
PHST- 2015/11/04 06:00 [pubmed]
PHST- 2016/09/23 06:00 [medline]
PHST- 2015/12/01 00:00 [pmc-release]
AID - 5825 [pii]
AID - 10.18632/oncotarget.5825 [doi]
PST - ppublish
SO  - Oncotarget. 2015 Dec 1;6(38):40719-33. doi: 10.18632/oncotarget.5825.